20 results on '"Wang, Yan-Yan"'
Search Results
2. Prognostic factors in colorectal liver metastases patients with various tumor numbers treated by liver resection: a single-center, retrospective study.
- Author
-
Chen FL, Wang YY, Liu W, and Xing BC
- Subjects
- Hepatectomy, Humans, Nomograms, Prognosis, Retrospective Studies, Colorectal Neoplasms pathology, Liver Neoplasms pathology
- Abstract
Background: Multiple liver metastases is considered a risk factor for overall survival of colorectal liver metastases patients (CRLM) after curative resection. However, whether the prognostic factors were constant in patients with various liver metastases (LM) numbers has not been adequately investigated. This retrospective study aimed to evaluate the changing of prognostic factors on overall survival (OS) in CRLM patients with various LM after curative resection., Methods: Patients who underwent liver resection for CRLM between January 2000 and November 2020 were retrospectively studied. They were divided into three subgroups according to LM numbers by X-tile analysis. Multivariable analysis identified prognostic factors in each subgroup. Nomograms were built using different prognostic factors in three subgroups, respectively. Performance of the nomograms was assessed according to the concordance index (C-index) and calibration plots. The abilities of different scoring systems predicting OS were compared by calculating the area under the time-dependent receiver operating characteristic (ROC) curve (AUC)., Results: A total of 1095 patients were included. Multivariable analysis showed tumor number increasing was an independent risk factor. Patients were subsequently divided into 3 subgroups according to the number of LM by X-tile analysis, namely solitary (n = 375), 2-4 (n = 424), and ≥ 5 (n = 296). The 3-year and 5-year OS rates were 64.1% and 54.0% in solitary LM group, 58.1% and 41.7% in 2-4 LM group, and 50.9% and 32.0% in ≥ 5 LM group, respectively (p < 0.001). In multivariable analysis, RAS mutation was the only constant independent risk factor in all subgroups. The nomograms were built to predict survival based on independent factors in three subgroups. The C-index for OS prediction was 0.707 (95% CI 0.686-0.728) in the solitary LM group, 0.695 (95% CI 0.675-0.715) in the 2-4 LM group, and 0.687 (95% CI 0.664-0.710) in the ≥ 5 LM group. The time-dependent AUC values of nomograms developed using different risk factors after stratifying patients by tumor number were higher than the traditional scoring systems without patient stratification., Conclusions: The prognostic factors varied among CRLM patients with different LM numbers. RAS mutation was the only constant risk factor. Building prediction models based on different prognostic factors improve patient stratification., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
3. Long disease-free interval diminishes the prognostic value of primary tumor stage for patients with colorectal cancer liver metastases.
- Author
-
Liu JM, Wang YY, Liu W, Xu D, Wang K, and Xing BC
- Subjects
- Hepatectomy adverse effects, Humans, Prognosis, Retrospective Studies, Survival Rate, Colorectal Neoplasms pathology, Liver Neoplasms
- Abstract
Background: It is assumed that the impact of primary tumor stage (PTS) on prognosis gradually weakens with increasing disease-free interval (DFI) from colorectal cancer resection to liver metastases., Methods: Data from 733 patients undergoing hepatectomy in the Hepato-pancreato-biliary Surgery Department I of Peking University Cancer Hospital were retrospectively analyzed. Early and late metastases were defined as DFI ≤ and >12 months, respectively., Results: In early metastases group, patients with T
4 stage had a significantly worse recurrence-free survival (RFS) and overall survival (OS) than those with T1-3 stage (P = 0.002 and P < 0.001, respectively). Patients with N1-2 stage disease also demonstrated a worse RFS and OS than those with N0 stage (P = 0.006 and P = 0.007, respectively). In late metastases group, patients with T4 and T1-3 stages as well as patients with N1-2 and N0 stages, had comparable RFS (P = 0.395 and P = 0.996, respectively) and OS (P = 0.387 and P = 0.684, respectively). T and N stages were independent prognostic predictors only in patients with early metastases., Conclusion: The impact of PTS on prognosis is diminished with increasing DFI and limited only to patients with early metastases., (Copyright © 2021. Published by Elsevier Ltd.)- Published
- 2022
- Full Text
- View/download PDF
4. Nomogram for prediction of the international study Group of Liver Surgery (ISGLS) grade B/C Posthepatectomy liver failure in HBV-related hepatocellular carcinoma patients: an external validation and prospective application study.
- Author
-
Ye JZ, Mai RY, Guo WX, Wang YY, Ma L, Xiang BD, Cheng SQ, and Li LQ
- Subjects
- Adolescent, Adult, Aged, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular virology, Female, Follow-Up Studies, Hepatitis B pathology, Hepatitis B virology, Hepatitis B virus, Humans, Liver Failure etiology, Liver Failure pathology, Liver Neoplasms pathology, Liver Neoplasms virology, Male, Middle Aged, Postoperative Complications etiology, Postoperative Complications pathology, Prognosis, Prospective Studies, Retrospective Studies, Risk Factors, Young Adult, Carcinoma, Hepatocellular surgery, Hepatectomy adverse effects, Hepatitis B complications, Liver Failure diagnosis, Liver Neoplasms surgery, Nomograms, Postoperative Complications diagnosis
- Abstract
Background: To develop a nomogram for predicting the International Study Group of Liver Surgery (ISGLS) grade B/C posthepatectomy liver failure (PHLF) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients., Methods: Patients initially treated with hepatectomy were included. Univariate regression analysis and stochastic forest algorithm were applied to extract the core indicators and reduce redundancy bias. The nomogram was then constructed by using multivariate logistic regression, and validated in internal and external cohorts, and a prospective clinical application., Results: There were 900, 300 and 387 participants in training, internal and external validation cohorts, with the morbidity of grade B/C PHLF were 13.5, 11.0 and 20.2%, respectively. The nomogram was generated by integrating preoperative total bilirubin, platelet count, prealbumin, aspartate aminotransferase, prothrombin time and standard future liver remnant volume, then achieved good prediction performance in training (AUC = 0.868, 95%CI = 0.836-0.900), internal validation (AUC = 0.868, 95%CI = 0.811-0.926) and external validation cohorts (AUC = 0.820, 95%CI = 0.756-0.861), with well-fitted calibration curves. Negative predictive values were significantly higher than positive predictive values in training cohort (97.6% vs. 33.0%), internal validation cohort (97.4% vs. 25.9%) and external validation cohort (94.3% vs. 41.1%), respectively. Patients who had a nomogram score < 169 or ≧169 were considered to have low or high risk of grade B/C PHLF. Prospective application of the nomogram accurately predicted grade B/C PHLF in clinical practise., Conclusions: The nomogram has a good performance in predicting ISGLS grade B/C PHLF in HBV-related HCC patients and determining appropriate candidates for hepatectomy.
- Published
- 2020
- Full Text
- View/download PDF
5. Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy.
- Author
-
Du QC, Hu CL, Wang YY, and Zhou Y
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor blood, Carcinoma, Hepatocellular blood, Carcinoma, Hepatocellular mortality, Female, Humans, Kaplan-Meier Estimate, Liver Neoplasms blood, Liver Neoplasms mortality, Male, Middle Aged, Platelet Count, Prognosis, ROC Curve, Retrospective Studies, Aspartate Aminotransferases blood, Blood Platelets chemistry, Carcinoma, Hepatocellular therapy, Chemoembolization, Therapeutic methods, Liver Neoplasms therapy
- Abstract
Purpose: To investigate the prognostic value of 17 platelet-based prognostic scores in patients with malignant hepatic tumors after TACE therapy., Methods: In total, 92 patients were divided into death group and survival group according to long-term follow-up results. The AUC was calculated to determine the optimal cut-off values for predicting prognosis. To determine better prognostic models, platelet-based models were analyzed separately after being showed as binary according to cut-off values. Cumulative survival rates of malignant hepatic tumors were calculated using Kaplan-Meier curves and differences were analyzed by the log-rank test. Univariate and multivariate analyses were performed to identify platelet-based prognostic scores associated with overall survival., Results: Univariate analysis showed that APGA, APRI, FIB-4, FibroQ, GUCI, King's score, Lok index, PAPAS, cirrhosis, number of tumors, vascular cancer embolus, AFP, ALP and APTT were significantly related to prognosis. A multivariate analysis showed that the APGA, number of tumors, ALP and APTT were independently associated with overall survival., Conclusion: This study showed that the APGA, a platelet-based prognostic score, was an independent marker of prognosis in patients with malignant hepatic tumors after TACE and was superior to the other platelet-based prognostic scores in terms of prognostic ability.
- Published
- 2019
- Full Text
- View/download PDF
6. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion.
- Author
-
Wang YY, Wang LJ, Xu D, Liu M, Wang HW, Wang K, Zhu X, and Xing BC
- Subjects
- Carcinoma, Hepatocellular diagnostic imaging, Carcinoma, Hepatocellular surgery, Combined Modality Therapy, Female, Hepatectomy, Humans, Kidney Function Tests, Liver Function Tests, Liver Neoplasms diagnostic imaging, Liver Neoplasms surgery, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Propensity Score, Radiofrequency Ablation, Survival Analysis, Carcinoma, Hepatocellular therapy, Chemoembolization, Therapeutic, Liver Neoplasms therapy, Patient Selection
- Abstract
Background: Microvascular invasion (MVI) is a powerful predictor of recurrence in patients who undergo liver resection for hepatocellular carcinoma (HCC). This study aimed to evaluate the efficacy of postoperative adjuvant transarterial chemoembolization (PA-TACE) in HCC patients with MVI, and further select potential patients benefitting from PA-TACE., Methods: Patients who had HCC with MVI and underwent liver resection between September 2004 and December 2015 were identified for further analysis. Overall survival (OS) and disease-free survival (DFS) were compared between patients treated with and without PA-TACE. Propensity score matching analysis was used to minimize inter-group differences., Results: A total of 176 patients with HCC and MVI were included. In both the entire and propensity-matched cohorts, OS and DFS were higher in PA-TACE group than non-TACE group (all P < 0.05). In subgroup analyses, PA-TACE showed efficacy in improving OS and DFS in HCC patients at early stage beyond Milan criteria and intermediate stage, but not in patients within Milan criteria. Multivariable analysis identified PA-TACE as a significantly favorable factor of OS and DFS for patients beyond Milan criteria, but not for those within Milan criteria., Conclusion: PA-TACE could be beneficial for patients who have HCC with MVI beyond Milan criteria, but not for those within Milan criteria., (Copyright © 2018. Published by Elsevier Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
7. Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma-authors' reply.
- Author
-
Wang YY, Zhong JH, Mao YL, Li LQ, and Xing BC
- Subjects
- Humans, Carcinoma, Hepatocellular, Liver Neoplasms
- Published
- 2019
- Full Text
- View/download PDF
8. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria.
- Author
-
Wang YY, Zhong JH, Xu HF, Xu G, Wang LJ, Xu D, Wang HW, Wang K, Xiang BD, Mao YL, Li LQ, and Xing BC
- Subjects
- Adult, Aged, Carcinoma, Hepatocellular pathology, Cohort Studies, Disease-Free Survival, Female, Follow-Up Studies, Hepatectomy trends, Humans, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Staging methods, Prognosis, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular surgery, Liver Neoplasms diagnosis, Liver Neoplasms surgery
- Abstract
Background: The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used staging system for hepatocellular carcinoma (HCC). However, the classifications of early (BCLC-A) and intermediate (BCLC-B) stage HCC remain controversial., Aim: To refine the staging of BCLC-A and -B., Methods: A total of 986 patients with HCC undergoing liver resection from two institutions formed the training cohort, and 694 from another institution were the validation cohort. Time-dependent receiver operating characteristic (ROC) curve analysis was performed to evaluate the performance of tumour size in predicting overall survival (OS), and determined the optimised cut-off. Discriminatory performance was evaluated using Harrell's concordance index (C-index)., Results: Patients with multiple tumours exceeding Milan criteria but within up-to-seven criteria had similar OS and disease-free survival (DFS) to those with multiple tumours meeting Milan criteria, and were assigned to the modified BCLC-A stage. The area under the ROC curve of tumour size for predicting OS was 0.778, and the diameter of 7 cm was the optimal cut-off to identify patients with single tumours who had higher OS than BCLC-B stage patients. Due to the similar OS, patients with single HCCs >7 cm were assigned to the modified BCLC-B stage. The C-indexes of the modified BCLC classification for OS and DFS were higher compared to the original version. The findings were supported by the validation cohort., Conclusions: The modified staging of BCLC-A and -B, based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria, could be more accurate to predict the prognosis of HCC patients. Liver resection could benefit patients with resectable multifocal HCCs beyond the Milan criteria., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
9. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma.
- Author
-
Qi LN, Xiang BD, Wu FX, Ye JZ, Zhong JH, Wang YY, Chen YY, Chen ZS, Ma L, Chen J, Gong WF, Han ZG, Lu Y, Shang JJ, and Li LQ
- Subjects
- Adult, Aged, Cadherins blood, Carcinoma, Hepatocellular genetics, Carcinoma, Hepatocellular pathology, Cell Movement genetics, Cell Proliferation genetics, Epithelial Cell Adhesion Molecule blood, Epithelial-Mesenchymal Transition genetics, Female, Gene Expression Regulation, Neoplastic, Hep G2 Cells, Humans, Liver Neoplasms genetics, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Invasiveness genetics, Neoplasm Invasiveness pathology, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor blood, Carcinoma, Hepatocellular blood, Liver Neoplasms blood, Neoplastic Cells, Circulating metabolism, Transaminases blood
- Abstract
To clarify the significance of circulating tumor cells (CTC) undergoing epithelial-mesenchymal transition (EMT) in patients with hepatocellular carcinoma (HCC), we used an advanced CanPatrol CTC-enrichment technique and in situ hybridization to enrich and classify CTC from blood samples. One hundred and one of 112 (90.18%) patients with HCC were CTC positive, even with early-stage disease. CTCs were also detected in 2 of 12 patients with hepatitis B virus (HBV), both of whom had small HCC tumors detected within 5 months. CTC count ≥16 and mesenchymal-CTC (M-CTC) percentage ≥2% prior to resection were significantly associated with early recurrence, multi-intrahepatic recurrence, and lung metastasis. Postoperative CTC monitoring in 10 patients found that most had an increased CTC count and M-CTC percentage before clinically detectable recurrence nodules appeared. Analysis of HCC with high CTC count and high M-CTC percentage identified 67 differentially expressed cancer-related genes involved in cancer-related biological pathways (e.g., cell adhesion and migration, tumor angiogenesis, and apoptosis). One of the identified genes, BCAT1, was significantly upregulated, and knockdown in Hepg2, Hep3B, and Huh7 cells reduced cell proliferation, migration, and invasion while promoting apoptosis. A concomitant increase in epithelial marker expression (EpCAM and E-cadherin) and reduced mesenchymal marker expression (vimentin and Twist) suggest that BCAT1 may trigger the EMT process. Overall, CTCs were highly correlated with HCC characteristics, representing a novel marker for early diagnosis and a prognostic factor for early recurrence. BCAT1 overexpression may induce CTC release by triggering EMT and may be an important biomarker of HCC metastasis. Significance: In liver cancer, CTC examination may represent an important "liquid biopsy" tool to detect both early disease and recurrent or metastatic disease, providing cues for early intervention or adjuvant therapy. Cancer Res; 78(16); 4731-44. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
10. Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure.
- Author
-
Xiang X, Qin HG, You XM, Wang YY, Qi LN, Ma L, Xiang BD, Zhong JH, and Li LQ
- Subjects
- Adult, Biomarkers, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Cell Line, Tumor, Female, Follow-Up Studies, Hepatitis B virology, Humans, Liver Cirrhosis etiology, Liver Cirrhosis pathology, Liver Neoplasms metabolism, Liver Neoplasms mortality, Liver Neoplasms pathology, Male, Middle Aged, NF-E2-Related Factor 2 metabolism, Neoplasm Staging, Neovascularization, Pathologic, Prognosis, RNA, Messenger genetics, RNA, Messenger metabolism, RNA-Binding Proteins metabolism, Signal Transduction, Survival Analysis, Tumor Burden, Aflatoxin B1 adverse effects, Carcinoma, Hepatocellular etiology, Gene Expression, Hepatitis B complications, Hepatitis B virus genetics, Liver Neoplasms etiology, RNA-Binding Proteins genetics
- Abstract
This study aims to clarify the relationship and mechanism between expression of autophagy-related protein P62 and prognosis of patients with hepatocellular carcinoma (HCC) involving chronic hepatitis B virus (HBV) infection and aflatoxin B1 (AFB1) exposure. HCC patients who underwent resection were divided into three groups: HBV(+)/AFB1(+) (n = 26), HBV(+)/AFB1(-) (n = 68), and HBV(-)/AFB1(-) (n = 14). The groups were compared in terms of mRNA and protein levels of P62, disease-free survival (DFS), and overall survival (OS) and the expression of NRF2, Nqo1, and AKR7A3 in P62 high-expression and low-expression group. HBV(+)/AFB1(+) group has lower DFS and OS, and higher P62 expression than in the other two groups. P62 expression generally correlated with elevated NRF2 and Nqo1 expression, and reduced AKR7A3 expression. Patients expressing high levels of P62 showed significantly lower DFS and OS rates than patients expressing low levels. HCC involving HBV infection and AFB1 exposure is associated with relatively high risk of tumor recurrence, and this poor prognosis may relate to high P62 expression. High P62 expression activates the NRF2 pathway, promotes tumor recurrence. The downregulation of AKR7A3 also reduced liver detoxification of aflatoxin B1., (© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
11. Optimizing stage of single large hepatocellular carcinoma: A study with subgroup analysis by tumor diameter.
- Author
-
Zhong JH, Pan LH, Wang YY, Cucchetti A, Yang T, You XM, Ma L, Gong WF, Xiang BD, Peng NF, Wu FX, and Li LQ
- Subjects
- Adult, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular surgery, Female, Follow-Up Studies, Hepatectomy mortality, Hospital Mortality, Humans, Liver Neoplasms mortality, Liver Neoplasms surgery, Male, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Analysis, Carcinoma, Hepatocellular pathology, Liver Neoplasms pathology, Tumor Burden
- Abstract
This study aims to refine the designation for single hepatocellular carcinoma (HCC) >5 cm by comparing the postresection prognosis of these patients with those who have a single-tumor ≤5 cm and those with stage B.Patients with a single-tumor were classified into subgroups based on diameter. Of the 1132 patients analyzed, 426 had a single-tumor >2 and ≤5 cm; 229, a single-tumor >5 and ≤8 cm; 52, a single-tumor >8 and < 10 cm; 150, a single-tumor ≥10 cm; and 275, stage B.Hospital mortality and complications increased with tumor size among the single-tumor subgroups and median survival decreased with increasing of tumor size. Overall survival (OS) among patients with a single-tumor >5 cm was significantly lower than among patients with a single-tumor >2 and ≤5 cm (P ≤ .001), but significantly higher than among patients with clearly stage B (P ≤ .001). Patients with a single-tumor >5 and ≤8 cm showed lower OS than patients with a single-tumor >2 and ≤5 cm (P < .001). Patients with a single-tumor >8 and <10 cm or a single-tumor ≥10 cm showed lower OS than patients with a single-tumor >5 and ≤8 cm (P = .033 and .006), and similar OS to patients with stage B (P = .323).Patients with a single-tumor >5 and ≤8 cm may be assigned to a new stage between early and intermediate. Patients with a single-tumor >8 cm may be assigned to intermediate stage.
- Published
- 2017
- Full Text
- View/download PDF
12. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study.
- Author
-
Zhong JH, Peng NF, You XM, Ma L, Xiang X, Wang YY, Gong WF, Wu FX, Xiang BD, and Li LQ
- Subjects
- Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, China, Female, Humans, Liver Neoplasms pathology, Liver Neoplasms surgery, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Tertiary Care Centers, Treatment Outcome, Carcinoma, Hepatocellular therapy, Chemoembolization, Therapeutic methods, Liver Neoplasms therapy
- Abstract
The current clinical reality of tumor stages and primary treatments of hepatocellular carcinoma (HCC) is poorly understood. This study reviewed the distribution of tumor stages and primary treatment modalities among a large population of patients with primary HCC. Medical records of patients treated between January 2003 and October 2013 for primary HCC at our tertiary hospital in China were retrospectively reviewed. A total of 6241 patients were analyzed. The distribution of Barcelona Clinic Liver Cancer (BCLC) stages was as follows: stage 0/A, 28.9%; stage B, 16.2%; stage C, 53.6%; stage D, 1.3%. The distribution of Hong Kong Liver Cancer (HKLC) stages was as follows: stage I, 8.4%; stage IIa, 1.5%; stage IIb, 29.0%; stage IIIa, 10.0%; stage IIIb, 33.6%; stage IVa, 3.4%; stage IVb, 2.5%; stage Va, 0.2%; stage Vb, 11.4%. The most frequent therapy was hepatic resection for patients with BCLC-0/A/B disease, and transarterial chemoembolization for patients with BCLC-C disease. Both these treatments were the most frequent for patients with HKLC I to IIIb disease, while systemic chemotherapy was the most frequent first-line therapy for patients with HKLC IVa or IVb disease. The most frequent treatment for patients with HKLC Va/Vb disease was traditional Chinese medicine. In conclusion, Prevalences of BCLC-B and -C disease, and of HKLC I to IIIb disease, were relatively high in our patient population. Hepatic resection and transarterial chemoembolization were frequent first-line therapies.
- Published
- 2017
- Full Text
- View/download PDF
13. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
- Author
-
Wang YY, Qi LN, Zhong JH, Qin HG, Ye JZ, Lu SD, Ma L, Xiang BD, Li LQ, and You XM
- Subjects
- Aged, Aldo-Keto Reductases, Biomarkers, Tumor genetics, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular virology, Disease-Free Survival, Female, Gene Expression Regulation, Neoplastic, Hepatectomy adverse effects, Hepatitis B virus pathogenicity, Humans, Liver Neoplasms pathology, Liver Neoplasms surgery, Liver Neoplasms virology, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Neoplasm Recurrence, Local virology, Prognosis, Risk Factors, Aldehyde Reductase genetics, Carcinoma, Hepatocellular genetics, Liver Neoplasms genetics, Neoplasm Recurrence, Local genetics
- Abstract
To clarify the relationship between aldo-keto reductase family 1 member B10 (AKR1B10) expression and early hepatocellular carcinoma (HCC) recurrence, this study detected AKR1B10 expression in tumor and adjacent non-tumor tissues from 110 patients with hepatitis B virus (HBV)-related HCC underwent liver resection and analyzed its correlations with clinicopathological characteristics and prognosis of these patients. Detected by quantitative reverse transcription polymerase chain reaction, AKR1B10 mRNA expression showed significantly higher in HCC tissues than in adjacent non-tumor tissues, with a low level in normal liver tissues. Similar results was confirmed at the protein level using immunohistochemistry and Western blotting. High AKR1B10 expression was negatively correlated with serum alpha-fetoprotein level and positively correlated with HBV-DNA level. Patients with high AKR1B10 expression had significantly higher disease-free survival than those with low expression within 2 years after liver resection. Multivariate analysis also confirmed high AKR1B10 expression to be a predictor of low risk of early HCC recurrence. In addition, high AKR1B10 expression was found to be a favorable factor of overall survival. These results suggest that AKR1B10 is involved in HBV-related hepatocarcinogenesis, but its high expression could predict low risk of early tumor recurrence in patients with HBV-related HCC after liver resection., Competing Interests: The authors declare no competing financial interests.
- Published
- 2017
- Full Text
- View/download PDF
14. Effects of interactions between environmental factors and KIF1B genetic variants on the risk of hepatocellular carcinoma in a Chinese cohort.
- Author
-
Chen JH, Wang YY, Lv WB, Gan Y, Chang W, Tian NN, Huang XH, Liu L, Yu XF, and Chen SD
- Subjects
- Adult, Aged, Alcohol Drinking adverse effects, Alcohol Drinking ethnology, Asian People genetics, Carcinoma, Hepatocellular ethnology, Carcinoma, Hepatocellular pathology, Case-Control Studies, Chi-Square Distribution, China, Female, Gene Frequency, Genetic Association Studies, Genetic Predisposition to Disease, Heterozygote, Homozygote, Humans, Liver Neoplasms ethnology, Liver Neoplasms pathology, Logistic Models, Male, Middle Aged, Odds Ratio, Phenotype, Risk Factors, Biomarkers, Tumor genetics, Carcinoma, Hepatocellular genetics, Gene-Environment Interaction, Kinesins genetics, Liver Neoplasms genetics, Polymorphism, Single Nucleotide
- Abstract
Aim: To examine the effect of the potential interaction between KIF1B variants (rs17401966 and rs3748578) and environmental factors on the risk of hepatocellular carcinoma (HCC) in a high-risk region in China., Methods: Three hundred and six patients with HCC and 306 hospital-based control participants residing in the Shunde region of Guangdong Province, China were enrolled. Clinical characteristics were collected by reviewing the complete medical histories from the patient archives, and epidemiological data were collected using a questionnaire and clinical examination. Two single nucleotide polymorphisms (SNPs) of KIF1B (rs17401966 and rs3748578) were chosen for the current study. All subjects were genotyped using a TaqMan real-time polymerase chain reaction. Multiplicative and additive logistic regression models were used to evaluate various gene-environment interactions., Results: Smoking, frequent consumption of raw freshwater fish, hepatitis B virus (HBV) infection, and a family history of HCC were important risk factors for HCC in this population. Chronic infection with HBV was the most important environmental risk factor for HCC [odds ratio (OR) = 12.02; 95% confidence interval (95%CI): 6.02-24.00]. No significant association was found between the KIF1B variants alone and the risk of HCC. Nevertheless, a significant additive effect modification was observed between rs17401966 and alcohol consumption (P for additive interaction = 0.0382). Compared with non-drinkers carrying either the AG or GG genotype of rs17401966, individuals classified as alcohol consumers with the AA genotype of rs17401966 had a significantly increased risk of HCC (OR = 2.36; 95%CI: 1.49-3.74)., Conclusion: The gene-environment interaction between the KIF1B rs17401966 variant and alcohol consumption may contribute to the development of HCC in Chinese individuals.
- Published
- 2016
- Full Text
- View/download PDF
15. Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular Carcinoma.
- Author
-
Lu SD, Wang YY, Peng NF, Peng YC, Zhong JH, Qin HG, Xiang BD, You XM, Ma L, and Li LQ
- Subjects
- Carcinoma, Hepatocellular immunology, Carcinoma, Hepatocellular surgery, China epidemiology, Female, Humans, Liver Neoplasms immunology, Liver Neoplasms surgery, Lymphocyte Count, Male, Middle Aged, Neoplasm Recurrence, Local immunology, Preoperative Period, Retrospective Studies, Risk Factors, Carcinoma, Hepatocellular mortality, Liver Neoplasms mortality, Neoplasm Recurrence, Local epidemiology
- Abstract
This study aims to clarify the prognostic value of the preoperative neutrophil-to-lymphocyte ratio (NLR) for patients with hepatocellular carcinoma (HCC) after potentially curative hepatic resection (HR). The prognostic value of the NLR for HCC patients has not been definitely reviewed by large studies, especially for those with different Barcelona Clinic Liver Cancer (BCLC) stages.A consecutive sample of 963 HCC patients who underwent potentially curative HR was classified as having low or high NLR using a cut-off value of 2.81. Overall survival (OS) and tumor recurrence were compared for patients with low or high NLR across the total population, as well as in subgroups of patients in BCLC stages 0/A, B, or C. Clinicopathological parameters, including NLR, were evaluated to identify risk factors of OS and tumor recurrence after potentially curative hepatic resection. Multivariate analyses were performed using the Cox proportional hazards model or subdistribution hazard regression model.Multivariate analyses showed that NLR (>2.81), tumor number (>3), incomplete capsule, serum albumin (≤35 g/L), alanine transaminase activity (>40 U/L), and macrovascular invasion were risk factors for low OS, whereas NLR (>2.81), tumor size (>5 cm), alpha fetal protein concentration (>400 ng/L), and macrovascular invasion were risk factors for low tumor recurrence. NLR > 2.81 was significantly associated with poor OS and tumor recurrence in the total patient population (both P < 0.001), as well as in the subgroups of patients in BCLC stages 0/A or B (all P < 0.05). Moreover, those with high NLR were associated with low OS (P = 0.027), and also with slightly higher tumor recurrence than those with low NLR for the subgroups in BCLC stage B (P = 0.058). Neither association, however, was observed among patients with BCLC stage C disease.NLR may be an independent predictor of low OS and tumor recurrence after potentially curative HR in HCC patients in BCLC stages 0/A or B.
- Published
- 2016
- Full Text
- View/download PDF
16. Historical Comparison of Overall Survival after Hepatic Resection for Patients With Large and/or Multinodular Hepatocellular Carcinoma.
- Author
-
Zhong JH, You XM, Lu SD, Wang YY, Xiang BD, Ma L, Wu FX, Yuan WP, Chen Y, and Li LQ
- Subjects
- Adolescent, Adult, Aged, Carcinoma, Hepatocellular pathology, Female, Follow-Up Studies, Hospital Mortality, Humans, Kaplan-Meier Estimate, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular surgery, Hepatectomy methods, Liver Neoplasms mortality, Liver Neoplasms surgery, Tumor Burden
- Abstract
The present study compared the efficacy of hepatic resection (HR) in patients with large hepatocellular carcinoma (HCC) and those with multinodular tumor and examined how that efficacy has changed over time in a large medical center.The intermediate stage of HCC comprises a highly heterogeneous patient population. Moreover, official guidelines have different views on the suitability of HR to treat such patients.A consecutive sample of 927 patients with preserved liver function and large and/or multinodular HCC who were treated by initial HR were divided into 3 groups: those with a single tumor ≥5 cm in diameter (n = 588), 2 to 3 tumors with a maximum diameter >3 cm (n = 225), or >3 tumors of any diameter (n = 114). Hospital mortality and overall survival (OS) in each group were compared for the years 2000 to 2007 and 2008 to 2013.Patients with >3 tumors showed the highest incidence of hospital mortality of all groups (P < 0.05). Kaplan-Meier survival analysis showed that OS varied across the 3 groups as follows: single tumor > 2 to 3 tumors > 3+ tumors (all P < 0.05). OS at 5 years ranged from 24% to 41% in all 3 groups for the period 2000 to 2007, and from 35% to 46% for the period 2008 to 2013. OS was significantly higher during the more recent 6-year period in the entire patient population, those with single tumor, and those with 3+ tumors (all P < 0.05). However, in patients with 2 to 3 tumors, OS was only slightly higher during the more recent 6-year period (P = 0.084).Prognosis can vary substantially for these 3 types of HCC. Patients with >3 tumors show the highest hospital mortality and lowest OS after HR. OS has been improving for all 3 types of HCC at our medical center as a consequence of improvements in surgical technique and perioperative management.
- Published
- 2015
- Full Text
- View/download PDF
17. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion.
- Author
-
Zhong JH, Rodríguez AC, Ke Y, Wang YY, Wang L, and Li LQ
- Subjects
- Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Humans, Liver Neoplasms mortality, Liver Neoplasms pathology, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Neovascularization, Pathologic mortality, Neovascularization, Pathologic pathology, Retrospective Studies, Survival Rate, Treatment Outcome, Carcinoma, Hepatocellular surgery, Hepatectomy, Liver Neoplasms surgery, Neoplasm Recurrence, Local surgery, Neovascularization, Pathologic surgery
- Abstract
This systematic review examined whether the available evidence justifies using hepatic resection (HR) during later stages of hepatocellular carcinoma (HCC), which contravenes treatment guidelines but is current practice at many medical centers.Official guidelines and retrospective studies recommend different roles for HR for patients with large/multinodular HCC or with HCC involving macrovascular invasion (MVI).Several databases were systematically searched for studies examining the safety and efficacy of HR for treating HCC involving a single large tumor (>5 cm) or multiple tumors, or for treating HCC involving MVI.We identified 50 studies involving 14, 808 patients that investigated the use of HR to treat large/multinodular HCC, and 24 studies with 4389 patients that investigated HR to treat HCC with MVI. Median in-hospital mortality for patients with either type of HCC was significantly lower in Asian studies (2.7%) than in non-Asian studies (7.3%, P < 0.001). Median overall survival (OS) was significantly higher for all Asian patients with large/multinodular HCC than for all non-Asian patients at both 1 year (81% vs 65%, P < 0.001) and 5 years (42% vs 32%, P < 0.001). Similar results were obtained for median disease-free survival at 1 year (61% vs 50%, P < 0.001) and 5 years (26% vs 24%, P < 0.001). However, median OS was similar for Asian and non-Asian patients with HCC involving MVI at 1 year (50% vs 52%, P = 0.45) and 5 years (18% vs 14%, P = 0.94). There was an upward trend in 5-year OS in patients with either type of HCC.HR is reasonably safe and effective at treating large/multinodular HCC and HCC with MVI. The available evidence argues for expanding the indications for HR in official treatment guidelines.
- Published
- 2015
- Full Text
- View/download PDF
18. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma after curative hepatectomy.
- Author
-
Wang YY, Huang S, Zhong JH, Ke Y, Guo Z, Liu JQ, Ma L, Li H, Ou BN, and Li LQ
- Subjects
- Adult, Aged, Carcinoma, Hepatocellular complications, Female, Hepatectomy, Humans, Liver Neoplasms complications, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Survival Analysis, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular surgery, Diabetes Complications mortality, Liver Neoplasms mortality, Liver Neoplasms surgery
- Abstract
Background: The influence of diabetes mellitus (DM) on the prognosis of patients with hepatocellular carcinoma (HCC) remains controversial. Here we investigated the impact of DM on the prognosis of such patients after curative hepatectomy., Methods: A consecutive cohort of 505 patients with HCC (134 with DM, 371 without) underwent curative hepatectomy were retrospectively evaluated. Postoperative morbidity and mortality, overall survival (OS) and disease-free survival (DFS) were compared between patients with or without DM. Independent prognostic predictors were identified using the Cox proportional hazards model., Results: Patients with or without DM showed similar morbidity and 30- and 90- day mortality after curative hepatectomy (all P>0.05), as well as similar DFS at 1, 3, 5 years (P = 0.781). However, the group of patients with DM showed significantly lower OS at 1, 3, 5 years than the group without DM (P = 0.038). Similar results were obtained in the propensity-matched cohort. Cox multivariate analysis identified DM as an independent predictor of poor OS, but not of poor DFS. We repeat compared OS and DFS for DM and non-DM subgroups defined according to the presence or absence of hepatitis B virus infection and cirrhosis. Similar results were obtained in all subgroups except the non-cirrhotic subgroup which showed patients with and without DM had similar OS., Conclusions: DM does not significantly affect the postoperative morbidity or mortality or the DFS of patients with HCC after curative hepatectomy. It is, however, associated with significantly lower OS, especially in patients with cirrhosis.
- Published
- 2014
- Full Text
- View/download PDF
19. Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension.
- Author
-
Zhong JH, Li H, Xiao N, Ye XP, Ke Y, Wang YY, Ma L, Chen J, You XM, Zhang ZY, Lu SD, and Li LQ
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Hepatocellular blood supply, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular surgery, Female, Humans, Hypertension, Portal complications, Hypertension, Portal surgery, Liver blood supply, Liver pathology, Liver Neoplasms blood supply, Liver Neoplasms complications, Liver Neoplasms surgery, Male, Middle Aged, Neoplasm Recurrence, Local blood supply, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Survival Analysis, Treatment Outcome, Carcinoma, Hepatocellular mortality, Hepatectomy, Hypertension, Portal mortality, Liver surgery, Liver Neoplasms mortality, Neoplasm Recurrence, Local mortality
- Abstract
Background & Aims: Official guidelines do not recommend hepatic resection (HR) for patients with hepatocellular carcinoma (HCC) and portal hypertension (PHT). This study aims to investigate the safety and efficacy of HR for patients with HCC and PHT., Methods: Mortality and survival after HR were analyzed retrospectively in a consecutive sample of 1738 HCC patients with PHT (n = 386) or without it (n = 1352). To assess the robustness of findings, we repeated the analysis using propensity score-matched analysis. We also comprehensively searched the PubMed database for studies evaluating the efficacy and safety of HR for patients with HCC and PHT., Results: The 90-day mortality rate was 6.7% among those with PHT and 2.1% among those without it (P<.001). Patients without PHT had a survival benefit over those with PHT at 1, 3, and 5 years (96% vs 90%, 75% vs 67%, 54% vs 45%, respectively; P = .001). In contrast, PHT was not associated with worse short- or long-term survival when only propensity score-matched pairs of patients and those with early-stage HCC or those who underwent minor hepatectomy were included in the analysis (all P>.05). Moreover, the recurrence rates were similar between the two groups. Consistent with our findings, all 9 studies identified in our literature search reported HR to be safe and effective for patients with HCC and PHT., Conclusions: HR is safe and effective in HCC patients with PHT and preserved liver function. This is especially true for patients who have early-stage HCC or who undergo minor hepatectomy.
- Published
- 2014
- Full Text
- View/download PDF
20. Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome.
- Author
-
Fan SH, Wang YY, Lu J, Zheng YL, Wu DM, Li MQ, Hu B, Zhang ZF, Cheng W, and Shan Q
- Subjects
- Animals, Blotting, Western, Cell Line, Tumor, Cell Movement drug effects, Cell Proliferation drug effects, Chromatography, High Pressure Liquid, Flavonoids chemistry, Flavonoids isolation & purification, Inflammasomes antagonists & inhibitors, Male, Mice, Mice, Inbred BALB C, Molecular Structure, NLR Family, Pyrin Domain-Containing 3 Protein, Plant Extracts chemistry, Plant Extracts isolation & purification, Carcinoma, Hepatocellular physiopathology, Carrier Proteins antagonists & inhibitors, Flavonoids pharmacology, Gentiana chemistry, Liver Neoplasms physiopathology, Lung Neoplasms secondary, Neoplasm Metastasis prevention & control, Plant Extracts pharmacology
- Abstract
The inflammasome is a multi-protein complex which when activated regulates caspase-1 activation and IL-1β secretion. Inflammasome activation is mediated by NLR proteins that respond to stimuli. Among NLRs, NLRP3 senses the widest array of stimuli. NLRP3 inflammasome plays an important role in the development of many cancer types. However, Whether NLRP3 inflammasome plays an important role in the process of hepatocellular carcinoma (HCC) is still unknown. Here, the anticancer effect of luteoloside, a naturally occurring flavonoid isolated from the medicinal plant Gentiana macrophylla, against HCC cells and the underlying mechanisms were investigated. Luteoloside significantly inhibited the proliferation of HCC cells in vitro and in vivo. Live-cell imaging and transwell assays showed that the migration and invasive capacities of HCC cells, which were treated with luteoloside, were significantly inhibited compared with the control cells. The inhibitory effect of luteoloside on metastasis was also observed in vivo in male BALB/c-nu/nu mouse lung metastasis model. Further studies showed that luteoloside could significantly reduce the intracellular reactive oxygen species (ROS) accumulation. The decreased levels of ROS induced by luteoloside was accompanied by decrease in expression of NLRP3 inflammasome resulting in decrease in proteolytic cleavage of caspase-1. Inactivation of caspase-1 by luteoloside resulted in inhibition of IL-1β. Thus, luteoloside exerts its inhibitory effect on proliferation, invasion and metastasis of HCC cells through inhibition of NLRP3 inflammasome. Our results indicate that luteoloside can be a potential therapeutic agent not only as an adjuvant therapy for HCC, but also, in the control and prevention of metastatic HCC.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.